scholarly journals AMCP Partnership Forum: What’s Next for Specialty Medication Benefit Design and Reimbursement

2020 ◽  
Vol 26 (10) ◽  
pp. 1206-1213
JAMA ◽  
2016 ◽  
Vol 316 (16) ◽  
pp. 1651 ◽  
Author(s):  
Michael E. Chernew ◽  
A. Mark Fendrick
Keyword(s):  

2015 ◽  
Vol 34 (3) ◽  
pp. 415-422 ◽  
Author(s):  
James C. Robinson ◽  
Timothy Brown ◽  
Christopher Whaley

Vaccines ◽  
2018 ◽  
Vol 6 (4) ◽  
pp. 78 ◽  
Author(s):  
Zhuliang Tao ◽  
Yong Li ◽  
Stephen Stemkowski ◽  
Kelly D. Johnson ◽  
Camilo J. Acosta ◽  
...  

Herpes zoster (HZ) vaccination is approved for adults aged 50+ for the prevention of HZ, but it is underutilized. The objective of this study was to evaluate the association between out-of-pocket cost and HZ vaccine utilization. Adults aged 65 or older enrolled for at least 12 months in Medicare Advantage/Part D (MAPD) and Medicare Part D only (PDP) plans from 1 January 2007 to 30 June 2014 were selected. Abandonment was defined as a reversed claim for HZ vaccine with no other paid claim within 90 days. Out-of-pocket costs used were actual amounts recorded in the claim. Overall, the HZ vaccine abandonment rate was 7.3%. Mean out-of-pocket costs were higher for individuals who abandoned versus those who did not ($88 (±$55) versus $80 (± $49)). Logistic regression indicated individuals with out-of-pocket costs of $80–$90 were 21% more likely (OR = 1.21, 1.16–1.27 95% CI), and those with out-of-pocket costs >$90 were 90% more likely (OR = 1.90, 1.85–1.96 95% CI) to abandon than those with out-of-pocket costs <$80. The models also suggested that socioeconomic, racial, and ethnic disparities in vaccine abandonment existed. Different vaccine targeting efforts and pharmacy benefit design strategies may be needed to increase use, improve adherence, and minimize disparities.


2005 ◽  
Vol 8 (3) ◽  
pp. 302
Author(s):  
BV Patel ◽  
RS Leslie ◽  
J Harriett ◽  
A Szczotka
Keyword(s):  

Vaccines ◽  
2017 ◽  
Vol 5 (1) ◽  
pp. 8 ◽  
Author(s):  
Charles Stoecker ◽  
Alexandra Stewart ◽  
Megan Lindley

2016 ◽  
Vol 73 (15) ◽  
pp. 1174-1179 ◽  
Author(s):  
Michelle T. Martin ◽  
Elena Telebak ◽  
Paige A. Taylor ◽  
Olga Volozhina

Abstract Purpose The project in which a clinical pharmacist enlisted the help of pharmacy students to create a team responsible for prior-authorization (PA) paperwork associated with hepatitis C virus (HCV) infection treatment is described. Summary Many insurance companies require completion of a time-consuming PA process for approval of high-cost specialty medications, such as those used in the treatment of HCV infection. A clinical pharmacist at an urban academic medical center recruited pharmacy students to assist with and streamline the HCV medication PA process. After training, the students developed a protocol to increase the efficiency of completing PA requests, appealing denials, obtaining PA extensions, and documenting progress in the electronic medical record to ensure continuity of care. The PA team collaborated with clinicians to document proof of medical need and worked with insurers, pharmacies, and patients to achieve timely approval and receipt of medications. From June 2014 to March 2015, three students spent 240 hours developing the PA protocol and completing 88 PA requests, with an overall medication approval rate of 87.7%; 18 patients were also referred to medication assistance programs. The PA team’s work allowed the clinical pharmacist to spend more time on clinical activities and scholarship, while the students increased their knowledge of HCV disease and HCV-targeted therapies and improved their skills in written and verbal communication with patients, providers, and insurance companies. Conclusion Pharmacy students successfully implemented a PA team to manage prescription approval for HCV medications with assistance from a clinical pharmacist.


Sign in / Sign up

Export Citation Format

Share Document